UPC
Universe Pharmaceuticals Inc. (UPC) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity is solid, with a 4.0 current ratio and 3.8 quick ratio, giving UPC more near-term flexibility than more levered peers.
Debt-to-equity is only 0.17, indicating a comparatively light equity leverage profile versus many industrial peers despite elevated net debt metrics.
The company’s cash conversion cycle is long at 428 days, but the balance-sheet liquidity cushion partially offsets working-capital strain better than weaker peers.
Weaknesses
ROIC is -3.2%, showing UPC is destroying value while stronger peers still compound capital at positive returns.
Net debt to EBITDA of 13.8x signals a highly stretched leverage position versus peers, constraining financial flexibility and raising refinancing risk.
A 428-day cash conversion cycle indicates severe working-capital inefficiency, leaving UPC structurally behind peers with faster cash generation.
Missing operating and gross margin data limits precision, but the available return and leverage metrics already point to weak underlying economics versus peers.
Opportunities
If UPC shortens its 428-day cash conversion cycle, it could release meaningful cash and narrow the gap with peers that convert working capital faster.
The low debt-to-equity ratio suggests room to improve capital structure resilience relative to peers if operating performance stabilizes.
Any improvement in invested capital returns would have outsized impact because the current negative ROIC leaves UPC well below peer value-creation levels.
Threats
Persistently negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest more aggressively and widen structural gaps.
High net debt to EBITDA leaves UPC more exposed than peers to tighter credit conditions, higher rates, or covenant pressure.
The very long cash conversion cycle increases the risk of liquidity stress versus peers if demand weakens or supplier terms tighten.
Limited margin disclosure adds uncertainty, but the current capital-efficiency profile already leaves UPC vulnerable to better-run competitors.
Overall Score
UPC’s structural positioning is weak versus peers because negative returns, extreme leverage, and poor cash conversion outweigh its relatively solid liquidity.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Universe Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
